株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

コンパニオン診断の世界市場 〜2022年:PCR・IHC・NGS・ISH

Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User - Global Forecast to 2022

発行 MarketsandMarkets 商品コード 538593
出版日 ページ情報 英文 172 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
コンパニオン診断の世界市場 〜2022年:PCR・IHC・NGS・ISH Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User - Global Forecast to 2022
出版日: 2017年08月01日 ページ情報: 英文 172 Pages
概要

世界のコンパニオン診断の市場は予測期間中、20.1%のCAGR (年間複合成長率) で推移し、2017年の26億1000万米ドルから、2022年には65億1000万米ドルの規模に成長すると予測されています。法規制上のガイドラインの整備、標的治療へのニーズの拡大、癌の罹患率の上昇、コンパニオン診断試験の開発に関する提携・協力関係の拡大などの要因が同市場の成長を推進しています。

当レポートでは、世界のコンパニオン診断の市場を調査し、市場の定義と概要、市場成長への各種影響因子および市場機会の分析、製品&サービス・技術・適応症・エンドユーザー・地域/主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 市場概要
  • 適応症別市場
  • 製品・サービス別市場
  • 技術別市場

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 市場分析:製品・サービス別

  • イントロダクション
  • アッセイキット・試薬
  • ソフトウェア・サービス

第7章 市場分析:技術別

  • イントロダクション
  • ポリメラーゼ連鎖反応 (PCR)
  • 免疫組織化学
  • in situハイブリダイゼーション
  • 次世代シーケンシング
  • その他

第8章 市場分析:適応症別

  • イントロダクション
    • 乳癌
    • 肺癌
    • 大腸癌
    • 黒色腫
    • 胃癌
    • その他
  • 神経科
  • 感染症
  • その他

第9章 市場分析:エンドユーザー別

  • イントロダクション
  • 医薬品・バイオ医薬品企業
  • リファレンスラボラトリー
  • その他

第10章 地域分析

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • その他
  • アジア太平洋
  • その他の地域

第11章 競合環境

  • イントロダクション
  • 市場ランキング
  • 競合リーダーシップマッピング
  • 競合ベンチマーキング
    • 製品ポートフォリオ
    • 事業戦略

第12章 企業プロファイル

  • F. HOFFMANN-LA ROCHE AG
  • AGILENT TECHNOLOGIES, INC.
  • QIAGEN N.V.
  • THERMO FISHER SCIENTIFIC INC.
  • ABBOTT LABORATORIES, INC.
  • BIOMERIEUX SA
  • DANAHER CORPORATION
  • ILLUMINA, INC.
  • MYRIAD GENETICS, INC.
  • ARUP LABORATORIES INC.
  • SYSMEX CORPORATION
  • HOLOGIC INC.
  • NOVARTIS AG
  • ALMAC GROUP
  • ABNOVA CORPORATION

第13章 付録

目次
Product Code: MD 5463

"Global companion diagnostics market projected to grow at CAGR of 20.1%"

The global companion diagnostics market is projected to reach USD 6.51 billion by 2022 from USD 2.61 billion in 2017, at a CAGR of 20.1%. The growth of this market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across the globe, and increasing collaborations and partnerships for companion diagnostics test development. However, uncertain reimbursement scenarios in different countries such as the U.S., the U.K., Japan, and Australia are expected to limit market growth.

The assay kits & reagents segment is expected to grow at the fastest CAGR'

On the basis of product and service, the companion diagnostics market is segmented into assay kits & reagents, and software & services. The assay kits & reagents segment accounted for the largest share in 2016 and is expected to register the highest CAGR during the forecast period. The large share can be attributed to its wide range of applications in platforms such as PCR, NGS, IHC, and ISH.

"The oncology segment to dominate the global companion diagnostics market with largest share and fastest CAGR"

Based on indication, the companion diagnostics market is further categorized into oncology, infectious diseases, neurology, and other indications (including cardiovascular, inflammatory, and inherited diseases). In 2016, the oncology segment accounted for the largest share and is also the fastest growing segment of the market; this is primarily attributed to the growing incidence of cancer that enhanced the focus on cancer research and also broadened the role of companion diagnostics in this field.

"The pharmaceutical and biopharmaceutical companies segment is expected to grow at the fastest CAGR"

On the basis of end user, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the market in 2016. This end-user segment is also expected to register the highest CAGR during the forecast period. The large share and growth of this market can be attributed to increasing and significant application of companion diagnostics in the drug development process.

"Asia-Pacific to witness the fastest growth during the forecast period (2017-2022)"

North America held the largest share of the global companion diagnostics market in 2016, while Asia-Pacific is expected to witness the highest growth during 2017 to 2022. Growing need for tailored therapeutics by the elderly population, increasing number of hospitals and diagnostic laboratories, and growing prevalence of life-threatening diseases are driving the growth of the companion diagnostics market in the Asia-Pacific region.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-45%, Tier 2-34%, and Tier 3-21%
  • By Designation - C-level-14%, Director Level-10%, and Others-76%
  • By Region - North America-40%, Europe-32%, Asia-Pacific-20%, and RoW-8%

Some of the major market players in the companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (U.S.), and QIAGEN N.V. (Netherlands) dominated the global companion diagnostics market. Some of the other players competing in this market are Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Danaher Corporation (U.S.), Almac Group (U.S.), and Sysmex Corporation (Japan).

Research Coverage:

The report analyzes the companion diagnostics market and aims at estimating market size and future growth potential of this market based on various segments such as product and service, type of medical device, application, and region. The report also includes an in-depth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product and service portfolios offered by the top players in the global companion diagnostics market. The report analyzes the global companion diagnostics market by product and service, technology, indication, end user, and region
  • Product/Service Enhancement/Innovation: Detailed insights on upcoming trends and new product/service launches in the global companion diagnostics market
  • Market Development: Comprehensive information on the lucrative emerging markets by product and service, type of medical device, application, and region
  • Market Diversification: Exhaustive information about new product or product enhancements, growing geographies, recent developments, and investments in the global companion diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, products, services, and capabilities of leading players in the global market.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED IN THE REPORT
  • 1.3. CURRENCY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. DATA TRIANGULATION
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
    • 2.2.2. KEY DATA FROM PRIMARY SOURCES
      • 2.2.2.1. Key industry insights
    • 2.2.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL COMPANION DIAGNOSTICS MARKET OVERVIEW
  • 4.2. COMPANION DIAGNOSTICS MARKET, BY INDICATION
  • 4.3. COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES
  • 4.4. COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Improvements in regulatory guidelines
      • 5.2.1.2. Growing need for targeted therapies
      • 5.2.1.3. Rising cancer incidence worldwide
      • 5.2.1.4. Increasing collaborations and partnerships for companion diagnostics test development
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Uncertain reimbursement scenarios in different regions
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Increasing demand for next-generation sequencing
      • 5.2.3.2. Increasing number of clinical trials to boost the adoption of companion diagnostics
      • 5.2.3.3. Emerging applications of companion diagnostics in other cancer indications, neurological disorders, infectious diseases, and cardiovascular diseases
    • 5.2.4. CHALLENGE
      • 5.2.4.1. Intellectual property rights protection issues

6. COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1. INTRODUCTION
  • 6.2. ASSAY KITS AND REAGENTS
  • 6.3. SOFTWARE & SERVICES

7. COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. POLYMERASE CHAIN REACTION
  • 7.3. IMMUNOHISTOCHEMISTRY
  • 7.4. IN SITU HYBRIDIZATION
  • 7.5. NEXT-GENERATION SEQUENCING
  • 7.6. OTHER TECHNOLOGIES

8. COMPANION DIAGNOSTICS MARKET, BY INDICATION

  • 8.1. INTRODUCTION
  • 8.2. ONCOLOGY
    • 8.2.1. BREAST CANCER
    • 8.2.2. LUNG CANCER
    • 8.2.3. COLORECTAL CANCER
    • 8.2.4. MELANOMA
    • 8.2.5. GASTRIC CANCER
    • 8.2.6. OTHER CANCERS
  • 8.3. NEUROLOGY
  • 8.4. INFECTIOUS DISEASES
  • 8.5. OTHER INDICATIONS

9. COMPANION DIAGNOSTICS MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
  • 9.3. REFERENCE LABORATORIES
  • 9.4. OTHER END USERS

10. COMPANION DIAGNOSTICS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. FRANCE
    • 10.3.3. U.K.
    • 10.3.4. REST OF EUROPE
  • 10.4. ASIA-PACIFIC
  • 10.5. REST OF THE WORLD

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
  • 11.2. MARKET RANKING ANALYSIS
  • 11.3. COMPETITIVE LEADERSHIP MAPPING
    • 11.3.1. VISIONARY LEADERS
    • 11.3.2. INNOVATORS
    • 11.3.3. DYNAMIC DIFFERENTIATORS
    • 11.3.4. EMERGING COMPANIES
  • 11.4. COMPETITIVE BENCHMARKING
    • 11.4.1. STRENGTH OF PRODUCT PORTFOLIO (FOR 25 PLAYERS)
    • 11.4.2. BUSINESS STRATEGY EXCELLENCE (FOR 25 PLAYERS)

Top 25 companies analyzed for this studies are - ABBOTT LABORATORIES, INC., AGILENT TECHNOLOGIES, INC., BIOMERIEUX SA, DANAHER CORPORATION, ILLUMINA INC., MYRIAD GENETICS, INC., QIAGEN N.V., ROCHE DIAGNOSTICS, THERMO FISHER SCIENTIFIC, INC., ARUP LABORATORIES INC., SYSMEX CORPORATION, HOLOGIC, INC., NOVARTIS AG, ALMAC GROUP, ABNOVA CORPORATION INVIVOSCRIBE TECHNOLOGIES, INC., FOUNDATION MEDICINE, INC., BIOGENEX LABORATORIES, INC., LABORATORY CORPORATION OF AMERICA HOLDINGS, MEDICAL & BIOLOGICAL LABORATORIES CO., LTD, CLARITY PHARMACEUTICALS, RESEARCHDX, INC., NEOGENOMICS LABORATORIES, INC., JANSSEN DIAGNOSTICS, SIEMENS HEALTHCARE DIAGNOSTICS INC.

12. COMPANY PROFILES (Overview, Business Overview, Business Strategy Excellence, Recent Developments)*

  • 12.1. F. HOFFMANN-LA ROCHE AG
  • 12.2. AGILENT TECHNOLOGIES, INC.
  • 12.3. QIAGEN N.V.
  • 12.4. THERMO FISHER SCIENTIFIC INC.
  • 12.5. ABBOTT LABORATORIES, INC.
  • 12.6. BIOMERIEUX SA
  • 12.7. DANAHER CORPORATION
  • 12.8. ILLUMINA, INC.
  • 12.9. MYRIAD GENETICS, INC.
  • 12.10. ARUP LABORATORIES INC.
  • 12.11. SYSMEX CORPORATION
  • 12.12. HOLOGIC INC.
  • 12.13. NOVARTIS AG
  • 12.14. ALMAC GROUP
  • 12.15. ABNOVA CORPORATION

*Details on MarketsandMarkets view, Overview, Overview, Business Overview, Business Strategy Excellence, and Recent Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS
  • 13.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE
  • TABLE 2: PARTNERSHIPS AND COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS
  • TABLE 3: LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS
  • TABLE 4: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2015-2022 (USD MILLION)
  • TABLE 5: COMPANION DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 6: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 7: EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 8: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 9: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 10: EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 11: GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 12: COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
  • TABLE 13: COMPANION DIAGNOSTICS MARKET FOR PCR, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 14: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 15: EUROPE: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 16: COMPANION DIAGNOSTICS MARKET FOR IHC, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 17: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 18: EUROPE: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 19: COMPANION DIAGNOSTICS MARKET FOR ISH, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 20: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 21: EUROPE: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 22: COMPANION DIAGNOSTICS MARKET FOR NGS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 23: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 24: EUROPE: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 25: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 26: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 27: EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 28: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 29: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 30: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 31: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 32: EUROPE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 33: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 34: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 35: EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 36: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 37: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 38: EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 39: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 40: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 41: EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 42: GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 43: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 44: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 45: EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 46: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 47: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 48: EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 49: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 50: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 51: EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 52: COMPANION DIAGNOSTICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 53: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 54: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 55: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 56: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 57: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 58: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 59: U.S.: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 60: U.S.: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 61: U.S.: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 62: U.S.: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 63: U.S.: COMPANION DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 64: CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 65: CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 66: CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 67: CANADA: COMPANION DIAGNOSTICS MARKET SIZE FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 68: CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 69: EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 70: EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 71: EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 72: EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 73: EUROPE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 74: EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 75: GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 76: GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 92  
  • TABLE 77: GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 78: GERMANY: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 79: GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 80: FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 81: FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 82: FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 83: FRANCE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 84: FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 85: U.K.: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 86: U.K.: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 87: U.K.: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 88: U.K.: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 89: U.K.: COMPANION DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 90: ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 91: ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 92: ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 93: ROE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 94: ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 95: APAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 96: APAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 97: APAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 98: APAC: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 99: APAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 100: ROW: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 101: ROW: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 106  
  • TABLE 102: ROW: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2015-2022 (USD MILLION)
  • TABLE 103: ROW: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 104: ROW: COMPANION DIAGNOSTICS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 105: RANK OF COMPANIES IN THE COMPANION DIAGNOSTICS MARKET, 2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BOTTOM UP APPROACH
  • FIGURE 3: TOP DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: MARKET DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017 VS. 2022
  • FIGURE 7: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017 VS. 2022
  • FIGURE 8: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2017 VS. 2022
  • FIGURE 9: GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2017 VS. 2022
  • FIGURE 10: GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET
  • FIGURE 11: INCREASING DEMAND FOR TARGETED THERAPY IS BOOSTING THE COMPANION DIAGNOSTICS MARKET
  • FIGURE 12: ONCOLOGY SEGMENT IS ESTIMATED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017
  • FIGURE 13: ASSAYS & REAGENTS SEGMENT IS ESTIMATED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017
  • FIGURE 14: POLYMERASE CHAIN REACTION IS ESTIMATED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017
  • FIGURE 15: COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16: INCREASING NUMBER OF NEW CANCER CASES WORLDWIDE, 2012 VS. 2015 VS. 2020
  • FIGURE 17: ASSAY KITS AND REAGENTS WILL CONTINUE TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 18: PCR WILL CONTINUE TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 19: ONCOLOGY SEGMENT TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 20: PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES WILL CONTINUE TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 21: GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 22: NORTH AMERICAN COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 23: EUROPEAN COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 24: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 25: COMPETITIVE LEADERSHIP MAPPING, 2017
  • FIGURE 26: F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2016)
  • FIGURE 27: AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 28: QIAGEN N.V.: COMPANY SNAPSHOT (2016)
  • FIGURE 29: THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 30: ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 31: BIOMERIEUX SA: COMPANY SNAPSHOT (2016)
  • FIGURE 32: DANAHER CORPORATION: COMPANY SNAPSHOT (2016)
  • FIGURE 33: ILLUMINA, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 34: MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 35: SYSMEX CORPORATION: COMPANY SNAPSHOT (2016)
  • FIGURE 36: HOLOGIC, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 37: NOVARTIS AG: COMPANY SNAPSHOT (2016)
Back to Top